1773 / 1835
• High-dose therapy followed by autologous stem cell transplantation
(ASCT) has been clearly identified as a reference treatment in
relapsing/refractory patients compared to standard chemotherapy
• However, many questions still remain:
definition of subgroups with different risk
type and number of salvage chemotherapy cycles
use of metabolic imaging in response definition
place of double ASCT
need to consider allogeneic transplantation in selected
patients
role of radiotherapy